Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Expects INNOVENT BIO's New Product Sales to Ramp up Next Yr, w/ $137.4 TP
Recommend 3 Positive 6 Negative 1 |
||||
|
||||
|
INNOVENT BIO (01801.HK) had six new products and the new indication for Sintilimab included in the 2025 National Reimbursement Drug List (NRDL), and its stock is officially included in the HSI effective today (8th), UBS said in its report. UBS believed the positive impacts of the above news include the prediction that sales of new products (IGF-1R, EGFR, BTK, ROS1, KRAS G12C, RET) will ramp up rapidly by 2026. Meanwhile, the stock's inclusion in the HSI will help boost liquidity. UBS gave the drug maker a target price of HKD137.4, with a Buy rating. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
